Streetbeat News

Regulatory

SPY

The US Core Consumer Price Index (CPI) for March reported a year-over-year increase of 3.8%, which is slightly above the estimated 3.7% but matches the prior month's figure of 3.8%.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:31 pm

SPY

The USA Consumer Price Index (CPI) for March increased by 0.4%, exceeding the estimated 0.3% and matching the prior month's increase of 0.4%.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:30 pm

SPY

President Biden announced plans to issue an executive order to limit asylum-seekers at the southern border, using Section 212(f) of the Immigration and Nationality Act. This move, aimed at addressing rising voter anger over border issues, does not require congressional approval. The decision is controversial, with internal debates about its legality and political implications.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:21 pm

PRPH

ProPhase Labs, Inc. (NASDAQ:PRPH) is set to launch its BE-Smart test for esophageal cancer detection in H2 2024. The test aims to provide early and cost-effective detection of esophageal adenocarcinoma (EAC), targeting a market size of $7 billion to $14 billion. The company is collaborating with mProbe Inc. and institutions like the Mayo Clinic for validation studies. The BE-Smart test, developed over six years, uses sophisticated proteomics for early detection and risk stratification of EAC, a cancer with high mortality rates. ProPhase plans to submit documentation for Advanced Diagnostic Laboratory Test (ADLT) application and aims for commercial launch following CPT code approval.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:09 pm

ADIL

Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced positive clinical results for AD04, its lead investigational drug for Alcohol Use Disorder (AUD), showing a strong safety profile, high patient compliance, and no significant adverse effects. The study compared AD04's liver safety profile to a placebo in subjects with AUD, revealing no significant changes in liver injury markers. Additionally, ADIL received a U.S. patent in February for AD04 targeting the serotonin transporter gene for opioid use disorder treatment.

Portfolio Pulse from Vandana Singh

April 10, 2024 | 12:00 pm

ADIL

Adial Pharmaceuticals announced a peer-reviewed publication showcasing safety data and high patient compliance in a clinical trial of AD04, a potential treatment for alcohol disorder.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:00 pm

MCHI

Fitch Ratings has downgraded China's sovereign credit outlook to negative from stable, maintaining an 'A+' rating, due to concerns over the nation's public finances amid economic uncertainties. This follows a similar action by Moody's in December. China's government debt is expected to rise significantly, with projections showing an increase to 61.3% of GDP in 2024 from 56.1% in 2023. Despite signs of economic recovery, Fitch warns of broad fiscal deficits and escalating government debt. The iShares MSCI China ETF (MCHI) saw a slight increase of 0.90% to close at $40.50.

Portfolio Pulse from Benzinga Neuro

April 10, 2024 | 11:35 am

CMND

Clearmind Medicine has filed a patent application with the USPTO for a psychedelic-based treatment targeting eating disorders. This move could potentially open new therapeutic avenues and markets for the company, emphasizing its commitment to innovating in the mental health treatment space.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 11:20 am

HOOK

HOOKIPA Pharma announced an investor call to summarize positive regulatory interactions with the U.S. FDA and the European Medicines Agency (EMA), indicating progress in their drug development and approval process.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 11:10 am

RDY

Dr. Reddy's Laboratories Ltd. has launched Nerivio, a drug-free migraine management device, in Germany through its subsidiary betapharm, marking its entry into digital therapeutics in Europe. Nerivio is FDA-approved and CE-mark certified.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 11:08 am